ATX-MS-1467 is a potential disease-modifying experimental therapy for relapsing-remitting multiple sclerosis (RRMS). The peptide-based therapeutic is designed to target up to 70 percent of people with MS who have a specific genetic profile.

ATX-MS-1467 consists of four short peptides derived from the basic protein of myelin, which is a key autoantigen in MS. ATX-MS-1467 aims to induce the immunological tolerance of the body’s T-cells to key autoantigens that are involved in the clinical development of MS. It seeks to reduce the attack by switching off (desensitizing) the autoimmune response to myelin. Gradually increased doses of ATX-MS-1467 could make the immune system adjust to their presence and stop the attack on myelin.

Studies Involving ATX-MS-1467

A second Phase 1 study was successfully completed (NCT01097668) after encouraging preliminary results of another Phase 1 study in six patients with SPMS. The second Phase 1 study aimed to assess the safety and biological parameters of ATX-MS-1467 in 43 RRMS patients. The primary endpoint was safety and tolerability which was determined by adverse effects and MRI scans. Identifying early signs of effectiveness was the second endpoint. MRI scans showed a significant decrease in new lesions, which is an early indicator of potential effectiveness.

A Phase 2 study (NCT01973491) has been completed, but the results are currently unavailable. More than 90 people with RRMS were enrolled in the open-label and proof-of-concept trial that was geared to evaluate the clinical and biological effects of ATX-MS-1467. The study objectives included changes in contrast-enhancing brain lesions at the start of the study and changes in annualized relapse rates. Results are expected to be announced soon.

ATX-MS-1467 is as an under-the-skin injection administered every two weeks.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

  1. https://www.apitope.com/multiple-sclerosis/
  2. https://www.mssociety.org.uk/atx-ms-1467
  3. http://apitope.com/apitope-announces-positive-results-clinical-trial-atx-ms-1467-relapsing-multiple-sclerosis/
  4. https://multiplesclerosisnewstoday.com/2016/10/19/apitope-regains-rights-to-potential-multiple-sclerosis-treatment-atx-ms-1467-from-merck